Overview

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

Status:
Completed

Trial end date:
2017-02-27

Target enrollment:

Participant gender:

Summary

The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with sickle cell disease

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ticagrelor